ArticleCureus2026
Long-Term Psychiatric Outcomes in Adult Patients With Migraine on Prophylactic Adjunctive Amitriptyline vs. Duloxetine: A Retrospective Cohort TriNetX Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine, a primary headache disorder, is a prevalent and debilitating chronic neurologic disorder. Migraine headaches are bidirectionally related to psychiatric conditions, such as anxiety and depression. Given these associations, further investigation into how medications used for migraine prophylaxis are associated with long-term psychiatric outcomes is warranted. Our study aims to examine, among patients with migraine, whether the use of adjunctive antidepressants (duloxetine or amitriptyline) in combination with topiramate is associated with differences in the incidence of long-term psychiatric outcomes, such as anxiety and depression. A retrospective cohort study with a five-year follow-up period was performed using TriNetX, a global federated health research network, and included patients aged ≥18 years with migraine who were started on either topiramate + duloxetine or topiramate + amitriptyline within one month on or after the first instance of documented migraine diagnosis in their electronic health record. After propensity score matching, both groups comprised 1241 patients. We found that patients on prophylactic topiramate + duloxetine had significantly greater five-year risks of anxiety disorder (unspecified), bipolar disorder, depressive episode, major depressive disorder, panic disorder, and post-traumatic stress disorder compared to patients on prophylactic topiramate + amitriptyline (p<0.05). In contrast, the risk of generalized anxiety disorder did not significantly differ between the two groups. There is limited data comparing duloxetine and amitriptyline when used for migraine prophylaxis in relation to subsequent psychiatric outcomes. Our study helps address this gap using real-world observational evidence. Our study may help inform future randomized clinical trials directly comparing these antidepressants for migraine prophylaxis, as well as provide a basis for future research on treatment selection, considering patients' severity of neurological symptoms, psychiatric risk factors, tolerability of adverse effects, and potential treatment benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.